

# TURKEY


## CERVICAL CANCER PROFILE

TOTAL POPULATION,  
FEMALE (2019): **42 260 000**

TOTAL DEATHS,  
FEMALE (2019): **212 000**


### Morbidity and Mortality

|  |              |
|--|--------------|
| Crude cervical cancer incidence per 100 000 women (2020):            | <b>5.9</b>   |
| Age-standardized cervical cancer incidence per 100 000 women (2020): | <b>4.8</b>   |
| Cumulative risk of cervical cancer, ages 0-74 (2020):                | <b>0.5%</b>  |
| Cervical cancer deaths (2019):                                       | <b>1 300</b> |
| Cervical cancer mortality-to-incidence ratio (2020):                 | <b>0.49</b>  |
| Population-based cancer registry exists (2021):                      | <b>Yes</b>   |



### Primary Prevention

#### HPV vaccination programme coverage among girls (2020)



**HPV vaccination is not included in the national vaccination schedule**

#### HPV vaccination programme (2020):

|   |           |
|---|-----------|
| HPV included in national vaccination programme: | <b>No</b> |
| Scale of vaccination programme:                 | -         |
| Year of introduction:                           | -         |
| Primary target cohort:                          | -         |


#### Related risk factors:

|  |            |
|--|------------|
| Tobacco use prevalence, women aged 15+ years (2020): | <b>19%</b> |
| Condom use at last high-risk sex (-):                | <b>ND</b>  |
| HIV incidence per 1000, women aged 15+ years (2020): | <b>ND</b>  |

### Secondary Prevention

|   |                    |
|---|--------------------|
| National screening programme for cervical cancer exists (2021):   | <b>Yes</b>         |
| Primary screening test used (2021):   | <b>HPV test</b>    |
| Target age range of programme (2021):   | <b>30-65 years</b> |
| Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): | <b>Yes</b>         |
| Clearly defined referral system exists from primary care to secondary and tertiary care (2021):                 | <b>Yes</b>         |

#### Screening for cervical cancer (2019)



**8 in 10 women have been screened for cervical cancer in the last 5 years**

### Treatment and Supportive Care

|   |            |
|---|------------|
| National guidelines on cervical cancer management exist (2021): | <b>Yes</b> |
|---|------------|

#### Cancer diagnosis and treatment services generally available (2021):

|   |            |
|---|------------|
| Cancer centre or cancer department at tertiary level: | <b>Yes</b> |
| Pathology services (laboratories):                    | <b>Yes</b> |
| Cancer surgery:                                       | <b>Yes</b> |
| Chemotherapy:   | <b>Yes</b> |
| Radiotherapy:   | <b>Yes</b> |

|  |           |
|--|-----------|
| Number of radiotherapy units per 10 000 cancer patients (2021):  | <b>12</b> |
| Number of brachytherapy units per 10 000 cancer patients (2021): | <b>1</b>  |

#### Number of medical staff (per 10 000 cancer patients):

|                                     |            |
|-------------------------------------|------------|
| Radiation oncologists (2019):       | <b>ND</b>  |
| Medical physicists (2019):          | <b>22</b>  |
| Surgeons (2011):                    | <b>290</b> |
| Radiologists (2019):                | <b>190</b> |
| Nuclear medicine physicians (2019): | <b>26</b>  |

#### Palliative care for patients with NCDs in the public health system generally available (2021):

|                                    |            |
|------------------------------------|------------|
| In primary health care facilities: | <b>Yes</b> |
| In community or home-based care:   | <b>Yes</b> |

Reported annual opioid consumption - excluding methadone - in oral morphine equivalence per capita (2017): **11mg**

### WHO Cervical Cancer Elimination Strategy Targets for 2030

**90% of girls fully vaccinated with the HPV vaccine by the age of 15**

**70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age**

**90% of women identified with cervical disease receive treatment**

ND = data not available

\* **Programme coverage:** % of national target population (among 9-14-year-old girls)

† **Coverage by age 15:** % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

[See Explanatory Notes for indicator descriptions.](#)